-
1.发明申请SOLUBLE ZCYTOR14, ANTI-ZCYTOR14 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 有权可溶性ZCYTOR14抗体ZIYTOR14抗体和结合合作伙伴及其使用方法公开(公告)号：US20110177083A1
公开(公告)日：2011-07-21
申请号：US13015304
申请日：2011-01-27
申请人： Scott R. Presnell , Steven K. Burkhead , Steven D. Levin , Rolf E. Kuestner , Zeren Gao , Stephen R. Jaspers , Janine Bilsborough
发明人： Scott R. Presnell , Steven K. Burkhead , Steven D. Levin , Rolf E. Kuestner , Zeren Gao , Stephen R. Jaspers , Janine Bilsborough
IPC分类号： A61K39/395 , A61K38/17 , A61P25/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/7155 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者多肽分子的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 ZcytoR14是IL-17A和IL-17F的常见受体。 本发明包括可溶性ZcytoR14，抗ZcytoR14抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17F，IL-17A或IL-17A和IL-17F两者的方法。
-
2.发明授权Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist 有权使用IL-17A和IL-17F拮抗剂治疗多发性硬化（MS）的方法公开(公告)号：US08268773B2
公开(公告)日：2012-09-18
申请号：US13015304
申请日：2011-01-27
申请人： Scott R. Presnell , Steven K. Burkhead , Steven D. Levin , Rolf E. Kuestner , Zeren Gao , Stephen R. Jaspers , Janine Bilsborough
发明人： Scott R. Presnell , Steven K. Burkhead , Steven D. Levin , Rolf E. Kuestner , Zeren Gao , Stephen R. Jaspers , Janine Bilsborough
IPC分类号： A61K38/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/7155 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者多肽分子的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 ZcytoR14是IL-17A和IL-17F的常见受体。 本发明包括可溶性ZcytoR14，抗ZcytoR14抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17F，IL-17A或IL-17A和IL-17F两者的方法。
-
3.发明授权Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation 有权可溶性ZcytoR14，抗ZcytoR14抗体和结合配偶体以及在炎症中使用的方法公开(公告)号：US07910540B2
公开(公告)日：2011-03-22
申请号：US11150533
申请日：2005-06-10
IPC分类号： A61K38/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/7155 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17F, IL-17A, or both IL-17A and IL-17F polypeptide molecules. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. ZcytoR14 is a common receptor for IL-17A and IL-17F. The present invention includes soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners, as well as methods for antagonizing IL-17F, IL-17A or both IL-17A and IL-17F using such soluble receptors, antibodies and binding partners.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17F，IL-17A或IL-17A和IL-17F两者多肽分子的活性。 IL-17A和IL-17F是参与炎症过程和人类疾病的细胞因子。 ZcytoR14是IL-17A和IL-17F的常见受体。 本发明包括可溶性ZcytoR14，抗ZcytoR14抗体和结合配偶体，以及使用这种可溶性受体，抗体和结合配偶体拮抗IL-17F，IL-17A或IL-17A和IL-17F两者的方法。
-
公开(公告)号：US06361985B1
公开(公告)日：2002-03-26
申请号：US09482180
申请日：2000-01-12
IPC分类号： C12N910
CPC分类号： C12N9/1051
摘要： The present invention relates to polynucleotide and polypeptide molecules for znssp6, a novel member of the galactosyltransferase family. The polypeptides, and polynucleotides encoding them, are cell-cell interaction and glycoprotein synthesis modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the znssp6 polypeptides.
摘要翻译： 本发明涉及用于znssp6（半乳糖基转移酶家族的新成员）的多核苷酸和多肽分子。 多肽和编码它们的多核苷酸是调节细胞 - 细胞相互作用和糖蛋白合成，并可用于递送和治疗。 本发明还包括针对znssp6多肽的抗体。
-
公开(公告)号：US06416988B1
公开(公告)日：2002-07-09
申请号：US09459133
申请日：1999-12-10
IPC分类号： C12N910
CPC分类号： C12N9/1051
摘要： The present invention relates to polynucleotide and polypeptide molecules for znssp2, a novel member of the galactosyltransferase family. The polypeptides, and polynucleotides encoding them, are cell-cell interaction and glycoprotein synthesis modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the znssp2 polypeptides.
摘要翻译： 本发明涉及用于znssp2（半乳糖基转移酶家族的新成员）的多核苷酸和多肽分子。 多肽和编码它们的多核苷酸是调节细胞 - 细胞相互作用和糖蛋白合成，并可用于递送和治疗。 本发明还包括针对znssp2多肽的抗体。
-
公开(公告)号：US06395890B1
公开(公告)日：2002-05-28
申请号：US09253316
申请日：1999-02-19
申请人： Paul O. Sheppard , Stephen R. Jaspers , Zeren Gao
发明人： Paul O. Sheppard , Stephen R. Jaspers , Zeren Gao
IPC分类号： C07H2104
CPC分类号： C07K14/475
摘要： This present invention is directed to polypeptide and polynucleotide molecules that encode a new connective tissue growth factor homolog polypeptide. The human polypeptides have been designated zCTGF4 and the mouse orthologs have been designated zCTGF2. The invention also includes antibodies, expression vectors, host cells expressing zCTGF4 and variants. Also included are methods for producing the polypeptides and using the polynucleotides and polypeptides.
摘要翻译： 本发明涉及编码新的结缔组织生长因子同源多肽的多肽和多核苷酸分子。 已经将人多肽称为zCTGF4，并将小鼠直向同源物称为zCTGF2。 本发明还包括抗体，表达载体，表达zCTGF4的宿主细胞和变体。 还包括用于产生多肽和使用多核苷酸和多肽的方法。
-
公开(公告)号：US20120294862A1
公开(公告)日：2012-11-22
申请号：US13534019
申请日：2012-06-27
申请人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
发明人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
IPC分类号： C07K16/46 , A61P29/00 , A61P11/06 , A61P25/00 , A61P1/00 , A61P19/02 , A61K39/395 , A61P37/00
CPC分类号： C07K16/244 , A61K2039/505 , A61K2039/507 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A，IL-17F和IL-23的活性。 拮抗剂包括结合IL-23并结合IL-17A或IL-17F的抗体和抗体片段，例如IL-17A和IL-17F交叉反应的抗体。 还公开了包括结合IL-23的抗体或抗体片段和在一个分子上结合IL-17A或IL-17F的抗体或抗体片段的拮抗剂。 还公开了结合IL-23和IL-17F但不结合IL-17A的抗体和抗体片段。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。
-
8.发明申请METHODS OF INHIBITING INFLAMMATION WITH ANTAGONISTS TO IL-17A, IL-17F, AND IL-23P19 有权用IL-17A，IL-17F和IL-23P19抑制炎症反应的方法公开(公告)号：US20110159589A1
公开(公告)日：2011-06-30
申请号：US13032501
申请日：2011-02-22
申请人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
发明人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
IPC分类号： C12N5/02
CPC分类号： C07K16/244 , A61K2039/505 , A61K2039/507 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A，IL-17F和IL-23的活性。 拮抗剂包括结合IL-23并结合IL-17A或IL-17F的抗体和抗体片段，例如IL-17A和IL-17F交叉反应的抗体。 还公开了包括结合IL-23的抗体或抗体片段和在一个分子上结合IL-17A或IL-17F的抗体或抗体片段的拮抗剂。 还公开了结合IL-23和IL-17F但不结合IL-17A的抗体和抗体片段。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。
-
9.发明授权公开(公告)号：US07910703B2
公开(公告)日：2011-03-22
申请号：US12111117
申请日：2008-04-28
申请人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
发明人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
IPC分类号： C12P21/08
CPC分类号： C07K16/244 , A61K2039/505 , A61K2039/507 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A，IL-17F和IL-23的活性。 拮抗剂包括结合IL-23并结合IL-17A或IL-17F的抗体和抗体片段，例如IL-17A和IL-17F交叉反应的抗体。 还公开了包括结合IL-23的抗体或抗体片段和在一个分子上结合IL-17A或IL-17F的抗体或抗体片段的拮抗剂。 还公开了结合IL-23和IL-17F但不结合IL-17A的抗体和抗体片段。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。
-
10.发明申请ANTAGONISTS TO IL-17A, IL-17F, AND IL-23P19 AND METHODS OF USE 有权对IL-17A，IL-17F和IL-23P19的拮抗作用及其使用方法公开(公告)号：US20080299129A1
公开(公告)日：2008-12-04
申请号：US12111117
申请日：2008-04-28
申请人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
发明人： Katherine E. Lewis , Scott R. Presnell , Steven D. Levin , George Robert Mabry, III , Stephen R. Jaspers , Monica J. Huber
CPC分类号： C07K16/244 , A61K2039/505 , A61K2039/507 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , Y10S530/809
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
摘要翻译： 本发明涉及阻断，抑制，降低，拮抗或中和IL-17A，IL-17F和IL-23的活性。 拮抗剂包括结合IL-23并结合IL-17A或IL-17F的抗体和抗体片段，例如IL-17A和IL-17F交叉反应的抗体。 还公开了包括结合IL-23的抗体或抗体片段和在一个分子上结合IL-17A或IL-17F的抗体或抗体片段的拮抗剂。 还公开了结合IL-23和IL-17F但不结合IL-17A的抗体和抗体片段。 IL-17和IL-23是涉及炎症过程和人类疾病的细胞因子。
-
-
-
-
-
-
-
-
-
搜索结果
67 条记录 (耗时 0.047 秒)